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The efficacy of prolonged administration of azithromycin was evaluated in a murine
model of lethal chronic toxoplasmosis. Mice were challenged intraperitoneally with
cysts of a moderately virulent strain of Toxoplasma gondii, observed for 4 weeks and
then allocated to the treatment or control group. All 26 animals given azithromycin
100 mg/kg/day for 100 days were protected compared with 19 of 25 control animals
which died (P < 0-001). Nineteen of the 20 mice in the treatment group survived for
an additional month while receiving the same azithromycin regimen but viable cysts
were identified in the brain tissue of these animals when they were killed. Although
there was no significant difference between the groups in terms of the number of
cysts in the brain, the administration of azithromycin was associated with a
reduction in brain inflammation. The concentrations of azithromycin in the brains
of five animals ranged from 0-7 to 2-3 /ig/g; there was no evidence of accumulation
even after 100 doses. Azithromycin merits further evaluation as primary or
secondary prophylaxis against toxoplasma encephalitis in individuals at risk of
developing this complication.
Introduction
Toxoplasma gondii is the most common cause of intracerebral mass lesions in patients
with the acquired immunodeficiency syndrome (AIDS). Depending on the prevalence
of latent toxoplasma infection in a given population, symptomatic toxoplasmosis of the
central nervous system is diagnosed in 3-40% of AIDS patients (Levy, Bredesen &
Rosenblum, 1985; Luft & Remington, 1988). The effective treatment of this infection is
complicated by frequent intolerance to conventional antimicrobial agents and the high
risk of relapse when therapy is discontinued (Leport et ai, 1986, 1988; Haverkos, 1987;
Wanke et al., 1987; Porter & Sande, 1992). Strategies to prevent cerebral toxoplasmosis
in AIDS patients with asymptomatic infection have therefore assumed increasing
importance, bearing in mind that therapy directed against growing tachyzoites in
symptomatic patients differs from prophylaxis in asymptomatic patients, the aim of
which is to prevent cyst rupture and the consequence thereof.
While the efficacy of the macrolides as treatment for AIDS patients with toxoplasma
encephalitis has been disappointing to date, it should not be assumed that these agents
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would not be effective as prophylaxis, a possibility which has been suggested in a recent
preliminary report (Durant et al., 1992). As this potential has not been adequately
investigated, the present study was undertaken to assess the ability of the prolonged
administration of azithromycin to prevent asymptomatic infection from progressing to
encephalitis in a murine model of toxoplasmosis.
Materials and methods
Antibiotic
Azithromycin dihydrate was provided in powder form by Pfizer Central Research
Division (Groton, CT, USA). It was mixed with saccharose (0-35 mg/dose), dissolved in
ethanol (10 mL/g of compound) and added to 4 mL of drinking water; the pH was
adjusted to 7-2 with 01 M NaOH.
Toxoplasma strain
The moderately virulent T. gondii strain PRU, which was originally isolated from an
AIDS patient with cerebral toxoplasmosis, was provided by Professor Pestre-Alexandre
(Limoges, France) and was maintained by serial intracerebral passage in mice. Cysts
were obtained from the brains of mice infected 4 months previously. Brain tissue was
ground through a 22-gauge needle (0-7 mm in diameter) and diluted in phosphate-
buffered saline (PBS) before inoculation.
Animal model
Infection was initiated by the inoculation of nine cysts suspended in 0-5 mL of PBS into
the peritoneal cavities of C57 BL/6J (H-2b) mice. Previous studies in our laboratory
demonstrated that this invariably leads to fatal chronic toxoplasmosis in untreated
animals, with death occurring in 80% of cases between 11 and 24 weeks after challenge.
Therapeutic protocol
Following inoculation, the mice were observed for 4 weeks. In order to prevent the
development of acute toxoplasmosis, sulphadiazine lOOmg/kg/day was added to the
drinking water of all mice from day 5 for 7 days. On day 30, the animals were randomly
allocated to the treatment or control group. The treatment group (n = 26) received
azithromycin lOOmg/kg/day in drinking water for 130 days. The control group
(n = 25) was maintained under the same conditions as the treatment group, except that
the mice did not receive azithromycin.
The mortality attributed to toxoplasmosis was assessed after 100 days of treatment
i.e. on day 131. Animals were examined daily and where death occurred during the day,
a post-mortem examination was performed immediately and the number of cysts in the
brain was determined as soon as possible after death. In the final stages of the disease,
neurological signs were often apparent and euthanasia was practised, when appro-
priate, in accordance with the highest standards of animal experimentation. On day
131, six control and six treated mice were randomly selected and killed by the
administration of a lethal dose of sodium thiopental; the brains of three animals in each
group were assessed in order to determine the number of cysts present and the brain,
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spleen, liver and lungs of the remaining three were processed for histological examina-
tion. On day 161, nine additional mice in each group were killed. Five were used to
determine the concentration of azithromycin in brain tissue, while the brains of the
other four were divided, one-half being used for the enumeration of cysts and the other
half for histological examination. On day 205, the remaining ten mice were killed and
samples of brain were inoculated into new mice in order to assess microbiological cure
(see below).
Determination of microbiological cure
For each of the ten mice in the two groups which survived to day 205, the brain was
removed, ground with PBS through a 22-gauge needle and inoculated intraperitoneally
into two new mice in order to assess the infectivity of the cysts. The inoculated animals
were observed for the next 30 days. Mice which died during this period underwent post-
mortem examinations for evidence of toxoplasmosis; the surviving mice were killed and
their brains examined for the presence of cysts.
Antibiotic assay
After macerating the brains on ice, azithromycin extraction was performed with
ethanol. Ethanol extracts were evaporated at 8-12°C and the residue dissolved in
200/zL of sodium buffer pH 80. The azithromycin concentrations in 100-^L aliquots
were determined by an agar diffusion method, described in the European
Pharmacopoeia (Anonymous, 1992), with Difco medium (pH 80) and Micrococcus
luteus as the indicator organism. Standards were prepared by dissolving azithromycin
in ethanol (2 g/L) and making serial dilutions in sodium buffer (pH 80). The zones of
inhibition were measured after the plates had been incubated at 37°C for 24 h; the
threshold of sensitivity of the assay was 0-4 mg/L. Antimicrobial activity in the brain of
one untreated animal (control) and in those of three non-infected mice which had been
given azithromycin lOOmg/kg for six consecutive days was also measured.
Histological examination
Immediately after death, the brain was removed from each animal, fixed in 10%
buffered formalin and embedded in paraffin. Four coronal sections (5 /im) were cut
from the cerebral hemispheres and stained with haematoxylin and eosin. The degree of
encephalitis was scored semi-quantitatively on an arbitrary scale of 0-3 according to
the following criteria: 3, extensive inflammation and necrosis; 2, extensive inflammation
without visible necrosis; 1, limited inflammation without visible necrosis; and 0, normal
tissue.
Brain cyst counts
Either the whole or one-half of each brain was suspended in PBS and passed ten times
through a 20-gauge (0-9 mm) needle and then a further ten times through a 22-gauge
needle. The resulting tissue sample was centrifuged at 350 g for 10 min at 4°C and the
total number of cysts in each brain was determined by microscopically screening
successive 20-/xL aliquots until the entire pellet had been examined.
114 J.-L. Dumas et al.
100
80
60
g 40
Azithromycin
(n = 26)
Control
(n = 25)
0 IB2 4 6 8 10 12 14 16
Weeks after starting treatment
Figure. Cumulative survival in mice with chronic toxoplasmosis according to treatment group.
Statistical analysis
Comparison of the groups in terms of survival was based on Kaplan-Meier curves.
Other results were compared with the Mantel-Cox log-rank test.
Results
Control animals
Nineteen of the 25 (76%) untreated mice died during the 100-day observation period
(Figure) and the six surviving animals were killed on day 131 in order to assess the
severity of infection. Of the ten post-mortem examinations which were performed,
there was histological evidence of pneumonitis in all cases. The numbers of brain cysts
ranged from 23 to 102 (mean 50-5) per brain (Table). Histological examination of three
animals killed on day 131 showed inflammatory infiltrates in the lungs, spleen and liver;
the encephalitis scores were 3 for two mice and 2 for one mouse (mean score 2-7). The
brain lesions were characterized by a perivascular leucocyte infiltration (principally
around intracerebral and meningeal blood vessels), the presence of microglial nodules
and foci of necrosis.
Table. Numbers of cysts in the brains of control and azithromycin-treated mice
Group
No. of days after
inoculation
No. of mice which
died or were
killed
No. of brain cysts
per mouse
Control
Treated
81
93
94
95
96
113
130
130
160
1
2
1
1
1
1
3
3
4
31
41, 56
42
23
102
52
97,46, 15
46, 32, 22
96, 32, 26, 26
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Treated animals
All 26 of the mice which received azithromycin survived and remained asymptomatic
throughout the 100-day observation period; the difference between the two groups in
terms of the incidence of mortality was therefore highly significant (P < 0001). One
mouse died from toxoplasmosis on day 141 i.e. after 110 days of therapy. The numbers
of cysts in the brains of the seven mice killed on days 131 and 161 ranged from 22 to 96
per brain (Table); the mean of 40 cysts per brain was not significantly different from
that for the untreated animals. Histological examination revealed inflammatory infil-
tration of the liver and lungs and the encephalitis scores were 0, 1 and 1 for the three
mice killed on day 131 and 0, 0, 1 and 2 for the four mice killed on day 161 (mean score
0-7).
Ten mice survived until day 205, 43 days after azithromycin administration was
discontinued, and were used to assess eradication of the pathogen. Three of the 20
reinoculated mice died from acute toxoplasmosis within 30 days of the challenge and
cysts were detected in the brains of the remaining 17 animals when they were killed.
The azithromycin concentrations in the brains of the five mice killed on day 161 were
0-7, 0-8, 0-9, 11 and 2-3 pg/g; no antibiotic was detected in serum samples which were
also obtained from these animals. There was no inhibitory activity in the brain tissue of
the untreated mouse and the concentrations of azithromycin in the brains of the three
non-infected mice were 1 -6, 1 -9 and 1 -9 /ig/g.
Discussion
A murine model was chosen for the present study because of the resemblance to the
disease in humans; in both cases, the untreated host remains asymptomatic for several
months before developing a fatal infection which is characterized by neurological
complications in the final stages. Azithromycin was selected because of the following
properties: prolonged inhibition of the replication of intracellular tachyzoites (Cham-
berland, Kirst & Current, 1991); in-vitro activity against cyst forms (Huskinson-Mark,
Araujo & Remington, 1991); high tissue specificity, with concentrations in the brain
which are almost ten-fold higher than those in serum after oral dosing (Araujo,
Shepard & Remington, 1991); significant intracellular accumulation (Gladue el ai,
1989); and potent activity in experimental murine toxoplasmosis (Araujo, Guptill &
Remington, 1988; Araujo et al., 1991; Derouin et al., 1992). A number of additional
observations also suggested that azithromycin might be suitable in this context: a
prolonged half-life (Girard et al., 1987), thereby allowing a simplified dosing schedule;
good tolerability; lack of effect on zidovudine disposition in patients with AIDS (Chave
et al., 1992); and potential activities against cryptosporidium and the Mycobacterium
avium complex (Brown et al., 1993; Vargas et al., 1993). The 100-mg/kg/day dosage was
used because it corresponds to that which is appropriate for man after size correction.
Prolonged administration of oral azithromycin 100 mg/kg/day reduced the incidence
of mortality but failed to produce microbiological cure in this murine model of chronic
toxoplasmosis. Efficacy in terms of reducing mortality was demonstrated although the
dosage used was lower than that (c. 200 mg/kg/day) previously shown to be effective as
therapy for the acute form of the disease (Araujo et al., 1991).
The experimental infection developed for use in the present study should be regarded
as a model of chronic systemic toxoplasmosis involving several organs, most notably
the liver, spleen, lungs and brain. Consequently, we were unable to identify the precise
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cause of death although, in all verified cases, severe interstitial lung infiltration and the
histological features of encephalitis, consistent with fatal toxoplasmosis, were observed.
On day 131, the mean numbers of cysts in the brains of the six mice in the control
and treatment groups were 50-5 and 40 respectively, values which were not significantly
different. On the other hand, the administration of azithromycin was clearly associated
with a reduction in cerebral inflammation. From these observations, we conclude that
the protective effect of azithromycin was not due to the direct inhibition of brain cyst
multiplication and that there is no correlation between the number of cysts in the brain
and mortality. In a previous study involving a similar murine model, immunochemistry
techniques were used to demonstrate the presence of toxoplasma antigen and extra-
cystic toxoplasma tachyzoites within foci of acute brain inflammation, predominantly
in relation to areas of perivascular leucocyte infiltration (Chang, Pechere & Piguet,
1992). AIDS patients with cerebral toxoplasmosis present not only with brain cysts but
also with extra- and intracellular tachyzoites (identified by immunochemistry), micro-
nodules surrounding scattered cysts and free tachyzoites (Lang et al., 1989). On the
basis of these findings, we suggest that the inflammatory reaction observed in the brain
is a host response to the growth and spread of extracystic tachyzoites and, as shown in
in-vitro studies (Chang & Pechere, 1988; Chamberland et al., 1991), that azithromycin
would be active against this form of the parasite. However, it is not clear whether the
extracystic organisms associated with brain inflammation originated from local cyst
disruption, from organs other than the brain, particularly the lungs (implying that the
brain was infected secondarily via the systemic circulation), or from both of these
sources. The second possibility is supported by the following evidence: brain cysts are
not normally surrounded by inflammatory infiltrates, which tend to predominate in
proximity to blood vessels; ruptured brain cysts are rarely seen on thin sections; and
T. gondii can be demonstrated in the blood of immunosuppressed patients with severe
toxoplasmosis.
The present study confirms the previously demonstrated antitoxoplasma activity of
azithromycin. This agent has been shown to inhibit the replication of intracellular
tachyzoites (Chang & Pechere, 1988; Chamberland et al., 1991) and to produce an
effect which is more prolonged than those of 23 other macrolides tested in parallel
(Chamberland et al., 1991). It has also been shown to kill intracystic bradyzoites
in vitro after 6 days of incubation (Huskinson-Mark et al., 1991). In mice infected with
the highly virulent RH strain of T. gondii, azithromycin, administered in dosages of
200 mg/kg/day for 10 days, effectively prevented death from this organism and the
same regimen also protected 80% of mice infected intracerebrally with the moderately
virulent C56 strain (Araujo et al., 1988). In addition, azithromycin was superior to both
roxithromycin and spiramycin in terms of protecting mice against death from acute
toxoplasmosis (Araujo et al., 1991). This enhanced efficacy might be related to
improved intrinsic antitoxoplasma activity or, alternatively, to higher tissue specificity.
In accord with earlier observations (Araujo et al., 1991), we detected azithromycin in
the brains of all animals in concentrations which are known to be effective against
susceptible organisms. However, in the present study, azithromycin, even when
administered for periods of more than 3 months, failed to produce a microbiological
cure, as demonstrated by the presence of cysts in the brain; its effect was confined to
protecting mice against a fatal outcome.
Toxoplasma encephalitis is a severe, life-threatening infection, particularly in AIDS
patients, and the identification of effective preventive measures must be a priority. Our
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observations suggest that azithromycin warrants further evaluation as primary or
secondary prophylaxis in individuals at risk of developing this complication.
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